NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis $2.80 +0.04 (+1.27%) As of 12:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Absci Stock (NASDAQ:ABSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Absci alerts:Sign Up Key Stats Today's Range$2.73▼$2.8250-Day Range$2.66▼$3.2252-Week Range$2.01▼$6.33Volume1.60 million shsAverage Volume2.84 million shsMarket Capitalization$356.53 millionP/E RatioN/ADividend YieldN/APrice Target$8.40Consensus RatingBuy Company OverviewAbsci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Read More… Absci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreABSI MarketRank™: Absci scored higher than 37% of companies evaluated by MarketBeat, and ranked 644th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAbsci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbsci has only been the subject of 2 research reports in the past 90 days.Read more about Absci's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.89) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -3.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Absci's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.01% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Absci has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted22.01% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Absci has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly. News and Social Media1.5 / 5News Sentiment0.62 News SentimentAbsci has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Absci this week, compared to 3 articles on an average week.Search InterestOnly 12 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Absci insiders have not sold or bought any company stock.Percentage Held by Insiders10.49% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Email Address ABSI Stock News HeadlinesAnalysts Set Absci Corporation (NASDAQ:ABSI) Price Target at $8.40June 19, 2025 | americanbankingnews.comAssessing Absci: Insights From 6 Financial AnalystsMay 17, 2025 | nasdaq.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 24, 2025 | Crypto Swap Profits (Ad)Earnings call transcript: Absci Q1 2025 sees stock surge post-earningsMay 15, 2025 | investing.comAbsci Corporation (ABSI) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAbsci Reports Business Updates and First Quarter 2025 Financial and Operating ResultsMay 13, 2025 | globenewswire.comAbsci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel DiseaseMay 13, 2025 | globenewswire.comAbsci Stock Short Interest Report | NASDAQ:ABSI | BenzingaApril 21, 2025 | benzinga.comSee More Headlines ABSI Stock Analysis - Frequently Asked Questions How have ABSI shares performed this year? Absci's stock was trading at $2.62 at the start of the year. Since then, ABSI stock has increased by 7.1% and is now trading at $2.8050. View the best growth stocks for 2025 here. How were Absci's earnings last quarter? Absci Corporation (NASDAQ:ABSI) announced its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. The company earned $1.18 million during the quarter, compared to analysts' expectations of $1.07 million. Absci had a negative net margin of 2,232.13% and a negative trailing twelve-month return on equity of 53.69%. Read the conference call transcript. When did Absci IPO? Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at $15.00-$17.00 per share. Who are Absci's major shareholders? Top institutional shareholders of Absci include ARK Investment Management LLC (8.59%), Fred Alger Management LLC (3.37%), Massachusetts Financial Services Co. MA (1.81%) and Sumitomo Mitsui Trust Group Inc. (1.17%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Redmile Group, Llc and Zachariah Jonasson. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Absci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Absci investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings5/13/2025Today6/23/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolNASDAQ:ABSI CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$8.40 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+204.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.11 million Net Margins-2,232.13% Pretax Margin-2,231.01% Return on Equity-53.69% Return on Assets-45.89% Debt Debt-to-Equity RatioN/A Current Ratio5.72 Quick Ratio5.72 Sales & Book Value Annual Sales$4.53 million Price / Sales77.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book1.77Miscellaneous Outstanding Shares127,560,000Free Float114,178,000Market Cap$352.07 million OptionableOptionable Beta2.06 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ABSI) was last updated on 6/24/2025 by MarketBeat.com Staff From Our PartnersSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredYour portfolio has a dangerous blind spot (fix it now)The next overnight crash could happen any day. Will you be protected or exposed? Register now to learn how som...Ninjacators | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Absci With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.